We examined the gene and protein expression of IRS 1 (insulin receptor substrate 1) in adipocytes from two groups of healthy individuals with an increased propensity for non-insulin-dependent diabetes mellitus (NIDDM): those with two first-degree relatives with diabetes and another group with massive obesity. A low expression of IRS 1 (<50% of the matched control group) was seen in Ϸ30% of both groups and these individuals were characterized by insulin resistance and its hallmarks: higher levels of insulin, glucose, and triglycerides. Two individuals with previously unknown NIDDM were diagnosed and both had low IRS 1 expression. Low IRS 1 protein expression was associated with low mRNA levels but not with the common Gly972Arg polymorphism of the IRS 1 gene. Taken together, our present and previous findings show that a low expression of IRS 1 in fat cells predicts insulin resistance and NIDDM. Furthermore, they support the likelihood that an impaired transcriptional activation may play a key role in the pathogenesis of NIDDM.-Carvalho, E., Jansson, P.-A., Axelsen, M., Eriksson, J. W., Huang, X., Groop, L., Rondinone, C., Sjöström, L., Smith, U. Low cellular IRS 1 gene and protein expression predict insulin resistance and NIDDM. FASEB J. 13, 2173-2178 (1999) 
Non-insulin-dependent diabetes mellitus (NIDDM) is caused by insulin resistance combined with an insufficient (relative to need) release of insulin (1) . Both genetic and environmental factors play a role in the pathogenesis of NIDDM. However, little progress has been made in unraveling the fundamental molecular and genetic factors. Several environmental factors have been defined including obesity, certain drugs, and smoking (1) (2) (3) . Genetic predisposition plays a key role since only some individuals exposed to the environmental risk factors develop NIDDM. Furthermore, healthy individuals who have two first-degree relatives with NIDDM have a three-to fivefold greater risk of developing the disease than those without a family history of diabetes (4) .
It is highly likely that NIDDM is a polygenic disorder involving proteins related to insulin secretory capacity and/or insulin sensitivity. Mutations have been identified in a few cases of NIDDM involving the insulin receptor (5), other proteins in insulin's signaling cascade (6) , or transcription factors (7) . However, no mutations of importance have been defined in the 'normal' NIDDM phenotypes, i.e., in at least 90% of the subjects.
A common polymorphism involving the important intracellular protein IRS 1 (insulin receptor substrate 1) has been reported (8) . IRS 1 is a docking protein that needs to become phosphorylated in order to activate the enzyme phosphatidyl inositol 3-kinase (PI3-kinase), a necessary step for the initiation of several effects of insulin such as glucose transport (9) . However, the IRS 1 polymorphism seems to be important only in its rare homozygous form or may be related to insulin resistance if combined with obesity (8) .
We have recently reported that fat cells from individuals with NIDDM exhibit a marked reduction in cellular protein expression and function of IRS 1 (10) . The 'backup' protein IRS 2 was then found to be the main docking protein for the intracellular propagation of the insulin signal including the activation of PI3-kinase (10). However, IRS 2 required a higher insulin concentration for activation, the hallmark of insulin resistance. This perturbation was not found in IDDM and thus is not related to hyperglycemia per se (10) .
We have now examined two groups of individuals with an increased propensity for NIDDM: healthy individuals with a massive family history, defined as two first-degree relatives with NIDDM; and individu-als with massive obesity. We found a marked reduction in IRS 1 protein content in ϳ30% of these two groups, which was associated with insulin resistance and the presence of other markers of the insulin resistance syndrome (11), including higher fasting insulin and triglyceride levels.
MATERIALS AND METHODS

Subjects
Two groups were recruited. The first group consisted of 44 healthy individuals, 22 of whom had a known family history of diabetes with at least two first-degree relatives with NIDDM. For each inclusion, a control subject was recruited and matched for body mass index (BMI), sex, and age. The control subjects had no known first-degree relatives with diabetes. The subjects were recruited from an advertisement placed in a daily newspaper. The study was approved by the Ethical Committee of the Göteborg University.
The second group of individuals was recruited from the Obesity Outpatient Unit. They all suffered from chronic massive obesity and were under evaluation for potential surgery with gastric banding. Clinical characteristics of the patient groups are shown in Tables 1 and 2 . Heredity for diabetes was common in the obese group but none had two first-degree relatives with known NIDDM.
Procedures
After admission to the study all patients underwent the following investigations. Body weight and length were recorded with standard techniques. Waist and hip circumferences were registered and the waist/hip ratio (WHR) was calculated (12) . Body composition was analyzed by bioimpedance in the relatives and their control subjects, and lean body mass (LBM) and body fat were calculated. All subjects then underwent a 75 g oral glucose tolerance test (OGTT), with measurements of blood levels of glucose and insulin at times 0 and 120 min. Fasting levels of triglycerides were analyzed using routine hospital techniques. Biopsies of the abdominal subcutaneous fat were obtained by the needle aspiration technique.
Relatives with a family history and their matched controls underwent additional investigations. Degree of insulin sensitivity was measured with the euglycemic, hyperinsulinemic clamp technique (13), the 'golden' standard for measuring insulin sensitivity, as previously reported in detail (14) . Briefly, insulin was infused into an intravenous cannula placed in the antecubital vein at a rate of 60 mU/m 2 /min. Blood glucose levels were maintained at 5.0 mmol/l by infusing glucose at a variable rate. After reaching a plateau (ϳ60 -90 min), the average rate of glucose infusion required to maintain euglycemia was calculated over 30 min (90 -120 min) and expressed per kilogram of LBM. Glucose was analyzed in arterialized venous blood using an automatic glucose analyzer (Yellow Springs Instrument, Yellow Springs, Ohio). Insulin was analyzed with a standard radioimmunoassay (Pharmacia, Uppsala, Sweden).
The relatives and their controls also underwent a test for oral lipid tolerance, as described previously (15) . The subjects consumed a mixed meal containing 51 g (49 E%) fat and 83 g (36 E%) carbohydrates. Serum triglyceride levels were measured before, during, and 6 h after food ingestion.
Fat cell analyses
The adipose specimens obtained from the needle biopsies were digested with collagenase to obtain isolated fat cells (16) . The cells were then lysed in the presence of protease inhibitors, followed by protein separation in 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as previously reported (10) . The protein content of IRS 1 was analyzed by immunoblotting with a carboxylterminal antibody (UBI, Lake Placid, NY) and the gels were scanned with a PhosphorImager. Quantitation was also verified with 125 I-protein A (10). A protein reduction of Ն50% as compared to control subjects was required for the definition of a low IRS 1 protein content.
Cell lysates were also analyzed for other key proteins in the intracellular signaling cascade for insulin such as the insulin receptor and the subunits of PI3-kinase. mRNA for IRS 1 was quantified on Northern blots using a cDNA probe against bases 1333-2335.
All evaluations of protein expression were performed by the same investigators (E.C. and U.S.), who were blinded to any information about the clinical and laboratory results of the subjects prior to the final analysis.
Screening for the Gly972Arg polymorphism
As the Gly972Arg polymorphism in IRS 1 creates a BstNI site, it can be detected by polymerase chain reaction (PCR) -restriction fragment length polymorphism. The PCR primers flanking this restriction site were5Ј-CTTCTGTCAGGTGTC-CATCC-3Ј (upstream) and 5-CTCTGCAGCAATGCCT-GTTC-3Ј (downstream). Genomic DNA (20 ng) was used in a 20 l PCR reaction containing 1ϫ PCR buffer, 150 M dNTP, and 0.4 M each of the primers, 1% (v/v) formamide and 0.5 U Taq DNA polymerase (Perkin Elmer, Norwalk, Conn.). The PCR was run at 94°C for 5 min, 30 cycles at 94°C for 30 s, 55°C for 30 s, 72°C for 30 s, and 72°C for 10 min. Ten microliter PCR products were incubated with 1 unit of BstNI for 3 h at 60°C in a final volume of 15 l. The samples were then run on a 2% agarose gel, stained with ethidium bromide, and analyzed under ultraviolet light.
Statistical methods
The Mann-Whitney test was used for comparisons between the groups. P Ͻ 0.05 was considered statistically significant. Conventional methods were used to calculate means Ϯse and the X 2 test was used to test for differences in distribution of the protein levels between the groups.
RESULTS
Relatives and control subjects Table 1 shows the clinical and laboratory characteristics of the two groups. They were of the same age, gender, BMI, and body fat. OGTT was normal in all subjects, and although the relatives tended to have slightly higher insulin levels at times 0 and 120 min, no significant differences were observed. Furthermore, insulin sensitivity measured with the euglycemic clamp was similar in both groups.
We identified 8/44 individuals, all males, with a marked reduction (Ն50%) in adipocyte IRS 1 con-tent: two control subjects (2/22ϭ9%) and six relatives (6/22ϭ27%). Figure 1 shows the IRS 1 protein expression in representative individuals. On average, it was reduced by ϳ70% in this group as compared to cells from the other subjects. This reduction in protein expression was probably due to a reduced transcription since IRS 1 gene expression (mRNA levels) was also markedly reduced when measured with Northern blots (Fig. 2) and RT-PCR (data not shown). We also investigated whether abnormalities in the expression of other key insulin signaling proteins could be detected, i.e., the insulin receptor and PI3 kinase subunits (p 85 and p 110), but this was not found. However, PI3-kinase activity associated with IRS 1 was reduced, as expected (data not shown).
We then compared the clinical characteristics of the group with low IRS 1 expression with the remaining 36 individuals. As shown in Table 1 , the group with low IRS 1 was differentiated from the other individuals by having insulin resistance and other markers of the insulin resistance syndrome. Although these groups had similar age, BMI, amount of body fat, and glucose levels, the group with low IRS 1 expression had significantly higher fasting insulin levels, a well-known marker of insulin resistance. The presence of insulin resistance was also verified by the euglycemic clamp results and calculation of the Insulin Sensitivity Index; both analyses showed ϳ30% lower levels in the group with low IRS 1 expression. Furthermore, this group had higher fasting triglyceride levels whereas the postprandial lipid tolerance was not significantly different. The group with low IRS 1 expression also had a significantly larger WHR than the other subjects despite similar BMI and amount of body fat (Table 1) . Since the group with low IRS 1 consisted of males only, WHR was also compared to that of males in the control group. However, the difference was still significant (PϽ0.02) 
DNA analyses for IRS 1 polymorphism
Polymorphism of the Gly 972 Gly Site for IRS 1 was examined in the eight individuals with low IRS 1 gene and protein expression as well as in eight control subjects without this abnormality. Only one individual with a low IRS 1 expression was found to have the Gly 972 Arg genotype, and all the rest were normal (Gly 972 Gly).
Obese group
The clinical and laboratory data of the obese individuals are shown in Table 2 . Compared with relatives and their control subjects (Table 1) , the obese group was older and had ϳfivefold greater amount of body fat. Their fasting insulin levels were higher but similar to the group of relatives and control subjects with low IRS 1 expression (Table 1) . Unfortunately, the obese group did not undergo a euglycemic clamp, but the degree of insulin resistance is indicated by the fasting insulin levels. We identified 6/20 (30%) obese individuals with low IRS 1 expression. The characteristics of this group are shown in Table 2 . They were of similar age and BMI as the group with normal IRS 1 expression. Their fasting insulin and glucose levels at 120 min during the OGTT were significantly higher (Table  2) , suggesting they were more insulin resistant. Furthermore, their fasting triglyceride levels tended to be higher. Two individuals with low IRS 1 expression were found during the OGTT to have previously undiagnosed NIDDM and an additional two had impaired glucose tolerance (IGT). No diabetes was detected in the group with normal IRS 1 expression, but five had IGT.
DISCUSSION
The present study shows that low IRS 1 gene and protein expression in fat cells can identify individuals with NIDDM as well as individuals at risk for NIDDM (i.e., with insulin resistance). These results markedly expand our previous findings that individuals with NIDDM, but not IDDM, frequently exhibit low IRS 1 expression in fat cells while other signaling molecules appear to be normally expressed (10) . Taken together, our findings show that low IRS 1 expression in fat cells is related to insulin resistance but is not secondary to hyperglycemia, obesity, or hyperinsulinemia per se. This latter point is important (17) and is documented by the finding that several obese individuals had insulin levels at least as high as the insulin-resistant lean group, but a normal expression of IRS 1 protein.
Impaired protein expression was more frequently found in young, lean individuals with a genetic predisposition for NIDDM than in the matched control subjects (27% vs. 9%), although this difference was not statistically significant (X 2 test, PϽ0.2) in this small group of individuals. Furthermore, low IRS 1 expression was common in the obese group (30%). One reason for this finding could be a common genetic predisposition for diabetes in the obese group. Such a possibility is supported by our previous finding in a prospective population study that a family history of diabetes was positively associated with overweight and weight gain over a 12 year follow-up period (18) .
In the obese group with reduced IRS 1 expression, we also found two individuals with previously unknown diabetes. However, not all individuals with an IGT exhibited this abnormality. It is well-established that IGT comprises a heterogeneous group where ϳone-third progresses toward NIDDM, one-third remains as IGT, and one-third reverses to normal glucose tolerance (19) . Thus, on balance, these results show that a reduced IRS 1 expression is related to insulin resistance in healthy, normoglycemic individuals and is also seen in NIDDM. An impaired effect of insulin can be expected when IRS 1 expression is low, since this docking protein is critical for the normal activation of PI3-kinase in response to insulin and, consequently, glucose transport and uptake (9). We have been able to use the adipocyte IRS 1 expression as a diagnostic procedure to characterize type of diabetes. Some individuals, presenting themselves with a typical clinical NIDDM phenotype but with normal IRS 1 expression, were found on the basis of subsequent analyses of insulin secretory capacity and presence of autoantibodies to be classified more precisely as IDDM (unpublished data).
Thus, this cross-sectional study suggests that low IRS 1 mRNA and protein expression in fat cells can identify individuals with NIDDM as well as those at risk (i.e., with insulin resistance). Larger studies are obviously required to corroborate this. This will also require a simpler assay since the system currently used is much too time-consuming and cumbersome.
An intriguing question is why low IRS 1 mRNA and protein expression in fat cells is associated with NIDDM and insulin resistance. It has been documented that the muscles, rather than fat tissue, are quantitatively important for glucose disposal (1). However, it may well be that adipose tissue produces or initiates factor(s) that in turn regulate insulin sensitivity and body glucose homeostasis. This is supported by recent findings in an animal model where ablation of adipose tissue development caused the animals to become diabetic (20) .
Adipose tissue is the main storage organ in the body for lipids, but it is highly unlikely that increased free fatty acid (FFA) levels can account for the present findings. This is also supported by the fact that fasting FFA levels were not significantly different among relatives and their controls (data not shown). The endocrine aspects of the adipose tissue seem much more probable. The fat cells produce leptin (21) , which seems to play an important role for hypothalamic functions and hormone release. However, leptin does not seem to produce insulin resistance (22) in the few short-term experiments that have been performed.
Another possibility is related to the production of cytokines, such as the interleukins and tumor necrosis factor ␣ (TNF-␣), by the adipose tissue. This is increased in obesity and immunoneutralization of TNF-␣ in obese animal models improves insulin resistance (23) . TNF-␣ has been shown to impair gene transcription for IRS 1 (24) . Thus, one possibility is that individuals with low IRS 1 gene and protein expression have an increased production of TNF-␣ and/or other cytokines by the adipose cells. This could, in turn, reduce insulin-stimulated glucose uptake by peripheral tissues. Furthermore, IRS 1 expression in the muscles may also be reduced, similar to what was seen in the fat cells. Although it has been reported that muscle IRS 1 protein expression does not appear to be reduced in NIDDM, impaired phosphorylation and PI3-kinase activation in response to insulin have been reported (25) .
How could a genetic predisposition become apparent in this scenario? It could be related to the activation of the gene(s) regulating the production rate and/or the cellular sensitivity to cytokines. In this scenario, the low IRS 1 protein expression would be a marker of the underlying defect. Another possibility is that the low IRS 1 protein reflects an impaired activation of transcription factors important for this and possibly other proteins. Mutations of the HNF transcription factors have been reported in subjects with maturity-onset diabetes in the young (MODY) (7) .
It is clear that the common polymorphism for the IRS 1 gene (Gly 972 Arg) cannot explain the present findings, since we found no relationship between genotypes and low IRS 1 protein expression. However, the WHR, a well-established marker of risk for NIDDM (26) , was significantly elevated in the group with low IRS 1 protein expression. Thus, the presence of this perturbation in the fat cells also seems to be linked to other established risk factors for NIDDM.
In summary, the present results show that low IRS 1 gene and protein expression is common in individuals with both genetic and environmental (obesity) risk for NIDDM, suggesting that this abnormality is located at a common pathogenetic pathway. Furthermore, the data support the concept that impaired transcriptional activation may play a key role in the development of insulin resistance and NIDDM.
